How Does Dupixent Work? Mechanism of Action Explained in Plain English

One of the most common questions patients have about Dupixent (dupilumab) is simply: how does it work? Why does one injection treat eczema, asthma, nasal polyps, esophagitis, and more — all at the same time? The answer comes down to a specific type of inflammation called type 2 inflammation, and two proteins that drive it: interleukin-4 (IL-4) and interleukin-13 (IL-13).

The Problem: Type 2 Inflammation

Inflammation is the immune system's natural response to threats — infection, allergens, irritants. But in conditions like atopic dermatitis, asthma, and chronic rhinosinusitis, the immune system overreacts with a specific pattern called type 2 inflammation.

Type 2 inflammation is driven by a branch of the immune system that responds to allergens and parasites. In people with conditions like eczema or eosinophilic asthma, this branch becomes chronically overactivated. It signals the body to produce massive amounts of inflammatory molecules — including IL-4 and IL-13 — which then cause the symptoms patients experience: intense itching, skin thickening and rash, airway narrowing, nasal polyp growth, and esophageal inflammation.

The Key Players: IL-4 and IL-13

IL-4 and IL-13 are cytokines — small proteins that immune cells use to send signals. Think of them as chemical messengers that carry instructions. In the context of type 2 inflammation:

IL-4 helps activate the T-helper 2 (Th2) immune cell pathway, amplifying the allergic inflammatory response and increasing IgE antibody production

IL-13 directly damages the skin barrier in eczema, triggers mucus overproduction in the airways, stimulates polyp growth in sinuses, and drives eosinophil-related inflammation in the esophagus

Together, IL-4 and IL-13 are the primary drivers of symptoms across all of Dupixent's approved indications. Block these two signals, and the cascade of inflammation is interrupted.

How Dupixent Blocks These Signals

Dupilumab (the active ingredient in Dupixent) is a fully human monoclonal antibody — a Y-shaped protein specifically engineered to bind to a single molecular target. Dupilumab binds to a shared receptor subunit called IL-4Rα (IL-4 receptor alpha), which is part of both the IL-4 receptor complex and the IL-13 receptor complex.

By blocking IL-4Rα, dupilumab prevents both IL-4 and IL-13 from delivering their inflammatory signals to cells. It works like plugging a keyhole — the keys (IL-4 and IL-13) can still exist in the body, but they can no longer turn the lock to activate inflammation. The downstream effects are:

In the skin: reduction in itch signaling, skin barrier dysfunction, and inflammatory cell recruitment — skin heals and clears

In the airways: reduction in eosinophil levels, mucus production, and airway narrowing — fewer and less severe asthma attacks

In the sinuses: shrinkage of nasal polyps, reduction in congestion and loss of smell symptoms

In the esophagus: reduction in eosinophil counts in the esophageal lining, improving swallowing and reducing food impaction

Is Dupixent an Immunosuppressant?

No — and this distinction matters clinically. Traditional immunosuppressants like cyclosporine, methotrexate, or oral steroids broadly reduce immune activity, which increases infection risk and can cause many side effects. Dupixent does not suppress the immune system broadly. It blocks a specific arm of the immune response — the type 2 inflammatory pathway — while leaving other immune functions intact.

This is why Dupixent has no boxed warning for infections, does not require lab monitoring, and is not associated with the same risk profile as other systemic treatments for eczema or asthma.

Why Does Dupixent Work for So Many Different Conditions?

All nine of Dupixent's FDA-approved indications share a common thread: they are driven, at least in part, by IL-4 and/or IL-13 signaling and type 2 inflammation. Atopic dermatitis, asthma, nasal polyps, EoE, prurigo nodularis, COPD with eosinophilic phenotype, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis all involve this same overactivated inflammatory pathway.

This is the concept of "treatable trait" medicine — rather than treating each disease organ-by-organ, you identify and address the shared underlying molecular mechanism. Blocking IL-4 and IL-13 interrupts that mechanism across multiple conditions simultaneously.

How Is Dupixent Different from Other Biologics?

Alternative biologics for eczema — like Adbry (tralokinumab) and Ebglyss (lebrikizumab) — block only IL-13, not IL-4. Dupixent is unique in blocking both cytokines by targeting their shared receptor. This dual blockade is thought to be responsible for its broad effectiveness across multiple conditions. See our comparison of Dupixent alternatives for more context on how these biologics compare.